Edoardo Bernkopf1, Vincenzo Capriotti2,3, Giulia Bernkopf4, Emilia Cancellieri5, Andrea D'Alessandro5, Alberto Vito Marcuzzo5, Caterina Gentili6, Giovanni Carlo De Vincentiis7, Giancarlo Tirelli5. 1. Dental Clinic, Via Garofolino 1, 36100, Vicenza, VI, Italy. 2. Otorhinolaryngology and Head and Neck Surgery Clinic, Azienda Sanitaria Universitaria Giuliano Isontina-ASUGI, Strada di Fiume 447, 39149, Trieste, Italy. capriotti.orl@gmail.com. 3. Otorhinolaryngology and Head and Neck Surgery Unit, ASST Bergamo Ovest, Treviglio-Caravaggio Hospital, Piazzale Ospedale Luigi Meneguzzo 1, 20047, Treviglio, BG, Italy. capriotti.orl@gmail.com. 4. Dental Clinic, Via Massaciuccoli 19, 00100, Rome, RM, Italy. 5. Otorhinolaryngology and Head and Neck Surgery Clinic, Azienda Sanitaria Universitaria Giuliano Isontina-ASUGI, Strada di Fiume 447, 39149, Trieste, Italy. 6. Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK. 7. Department of Otolaryngology, Bambino Gesù Children's Hospital, IRCCS, Rome, RM, Italy.
Abstract
PURPOSE: To assess the effect of oral splint therapy on audio-vestibular symptoms in patients with Menière's disease (MD) and temporomandibular disorder (TMD). METHODS: Retrospective case-control study. Treatment group: 37 patients with MD and TMD who received gnatological treatment. CONTROL GROUP: 26 patients with MD and TMD who had never received gnatological treatment. The number of vertigo spells in 6 months (primary endpoint), pure-tone audiometry average (PTA), MD stage, functional level, Dizziness handicap Index (DHI), Tinnitus handicap Index (THI) and Aural Fullness Scale (AFS) were compared at baseline and after 24 months according to groups. Analysis of Covariance was used to determine the treatment effect. RESULTS: Groups were comparable for demographic, clinical data, baseline PTAs and the number of vertigo spells. Analysis of covariance showed a significant effect of gnathological treatment on number of vertigo spells ([Formula: see text] = 0.258, p < 0.001), PTA ([Formula: see text] = 0.201, p < 0.001), MD stage ([Formula: see text] = 0.224, p < 0.001), functional level ([Formula: see text] = 0.424, p < 0.001), DHI ([Formula: see text] = 0.421, p < 0.001), THI ([Formula: see text] = 0.183, p < 0.001), but not for AFS ([Formula: see text] = 0.005, p = 0.582). The treatment group showed vertigo control of class A in 86.5% and class B in 13.5% of patients. In the control group, vertigo control was of class A in 19.2% of patients and class B in 11.5%, class C in 30.8%, class D in 11.5%, class E in 19.2% and class F in 7.7%. Classes of vertigo control differed significantly (X2 test, p < 0.001). CONCLUSIONS: Oral splint therapy could represent a viable treatment in patients with TMD and uncontrolled MD disease. The effects are maintained at least after 2 years.
PURPOSE: To assess the effect of oral splint therapy on audio-vestibular symptoms in patients with Menière's disease (MD) and temporomandibular disorder (TMD). METHODS: Retrospective case-control study. Treatment group: 37 patients with MD and TMD who received gnatological treatment. CONTROL GROUP: 26 patients with MD and TMD who had never received gnatological treatment. The number of vertigo spells in 6 months (primary endpoint), pure-tone audiometry average (PTA), MD stage, functional level, Dizziness handicap Index (DHI), Tinnitus handicap Index (THI) and Aural Fullness Scale (AFS) were compared at baseline and after 24 months according to groups. Analysis of Covariance was used to determine the treatment effect. RESULTS: Groups were comparable for demographic, clinical data, baseline PTAs and the number of vertigo spells. Analysis of covariance showed a significant effect of gnathological treatment on number of vertigo spells ([Formula: see text] = 0.258, p < 0.001), PTA ([Formula: see text] = 0.201, p < 0.001), MD stage ([Formula: see text] = 0.224, p < 0.001), functional level ([Formula: see text] = 0.424, p < 0.001), DHI ([Formula: see text] = 0.421, p < 0.001), THI ([Formula: see text] = 0.183, p < 0.001), but not for AFS ([Formula: see text] = 0.005, p = 0.582). The treatment group showed vertigo control of class A in 86.5% and class B in 13.5% of patients. In the control group, vertigo control was of class A in 19.2% of patients and class B in 11.5%, class C in 30.8%, class D in 11.5%, class E in 19.2% and class F in 7.7%. Classes of vertigo control differed significantly (X2 test, p < 0.001). CONCLUSIONS: Oral splint therapy could represent a viable treatment in patients with TMD and uncontrolled MD disease. The effects are maintained at least after 2 years.
Authors: Eric Schiffman; Richard Ohrbach; Edmond Truelove; John Look; Gary Anderson; Jean-Paul Goulet; Thomas List; Peter Svensson; Yoly Gonzalez; Frank Lobbezoo; Ambra Michelotti; Sharon L Brooks; Werner Ceusters; Mark Drangsholt; Dominik Ettlin; Charly Gaul; Louis J Goldberg; Jennifer A Haythornthwaite; Lars Hollender; Rigmor Jensen; Mike T John; Antoon De Laat; Reny de Leeuw; William Maixner; Marylee van der Meulen; Greg M Murray; Donald R Nixdorf; Sandro Palla; Arne Petersson; Paul Pionchon; Barry Smith; Corine M Visscher; Joanna Zakrzewska; Samuel F Dworkin Journal: J Oral Facial Pain Headache Date: 2014
Authors: J Nevoux; M Barbara; J Dornhoffer; W Gibson; T Kitahara; V Darrouzet Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2018-01-12 Impact factor: 2.080
Authors: Jose A Lopez-Escamez; John Carey; Won-Ho Chung; Joel A Goebel; Måns Magnusson; Marco Mandalà; David E Newman-Toker; Michael Strupp; Mamoru Suzuki; Franco Trabalzini; Alexandre Bisdorff Journal: J Vestib Res Date: 2015 Impact factor: 2.435
Authors: J Stechman-Neto; A L Porporatti; I Porto de Toledo; Y M Costa; P C R Conti; G De Luca Canto; L A Mezzomo Journal: J Oral Rehabil Date: 2016-01-08 Impact factor: 3.837
Authors: D Monzani; E Genovese; A Marrara; C Gherpelli; L Pingani; M Forghieri; M Rigatelli; T Guadagnin; E Arslan Journal: Acta Otorhinolaryngol Ital Date: 2008-06 Impact factor: 2.124
Authors: E A Al-Moraissi; R Farea; K A Qasem; M S Al-Wadeai; M E Al-Sabahi; G M Al-Iryani Journal: Int J Oral Maxillofac Surg Date: 2020-01-22 Impact factor: 2.789